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The hemoregulatory peptide PyroGlu-Glu-Asp-Cys-Lys (HPSb), which inhibits myelopoietic olony formation in vitro, is shown to be a sequence 
motif which is also part of the effector domain of Gi, proteins, Out of 8 synthetic peptides with sequence variations of HPSb, those with the closest 
similarity to the G,, sequence are biologically active. The inhibitory effect appears to be dependent on the blocked N-terminus. It is postulated 
that these peptides may interfere with signal transduction mediated by Gi= proteins. 
G-protein; Hemopoiesis; Hemoregulatory peptide 
1. INTRODUCTION 
The hemoregulatory peptide (HPSb) is an acidic pen- 
tapeptide which inhibits myelopoietic cell proliferation 
with high selectivity [l-4]. It seems to be secreted by 
mature granulocytes both in human and in animals [5]. 
The peptide may be the part of a general regulatory 
system mediated by negative feedback mechanisms, 
since structurally related peptides have a similar selec- 
tive inhibitory effect on epidermal cells [6] and 
hepatocytes [7]. 
Although the peptide is taken up by hemopoietic ells 
[8] and there is some evidence for a cell receptor [5], 
nothing is known about receptor physiology, inter- 
nalization or signal transduction mediated by the 
molecule. During the search for other active com- 
pounds, a series of peptides structurally related to the 
original HP5b were synthesized chemically. We report 
here that biologically active peptides have a close 
similarity to a five amino acid sequence in the effector 
domain of the a-subunit of three sequenced inhibitory 
G-proteins. 
The initial reason to search for protein sequences 
with homology to the hemoregulatory peptide was born 
out of the question whether such a small peptide could 
be encoded by a gene, or whether it would be generated 
by processing a larger polypeptide precursor. If such a 
precursor would have a different function in the cell, it 
might have been discovered already in a different con- 
text and could be retrieved from the current data bases. 
A second aspect of the search was of course the finding 
that sequence motif in perhaps well-characterized pro- 
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teins might provide us with hints how the 
hemoregulatory peptide could possibly function. 
2. MATERIALS AND METHODS 
2.1. Materials 
Altogether seven pentapeptides were synthesized as earlier describ- 
ed [5,8] and, following repurification, were obtained as 95-99% pure 
crystalline material (courtesy by Nycomed, Oslo). The peptides were 
dissolved in 0.9% NaCl containing 5 x 10e5 M Ca Nar EDTA, or 
low4 M mercaptoethanol to avoid dimerization. 
2.2. Hernopoietic cell culture 
A one-layer method with 10’ C3H mouse bone marrow cells plated 
in 0.35% agar in Eagle Dulbecco’s medium with 25% fetal calf serum 
and with mouse endotoxin stimulated serum as colony stimulating ac- 
tivity, was used as described earlier [3]. The numbers of colonies 
(over 50 cells) were counted after 7 days at 37°C and in 5% CO2 in 
air. 
2.3. Computer methods 
The pentapeptide sequences were searched with FastP against the 
MIPSX protein sequence data base of the Max-Planck-Institute for 
Biochemistry, Martinsried, FRG. The library contained at the time of 
the search 9807 entries with a total of 2457508 residues. The maximal 
possible score for the pentapeptide EEDCK was 29 using the Dayhoff 
MD matrix. The average score was 8.3 with a standard deviation of 
6.62. The top score (bovine guanine nucleotide binding protein) was 
28. The search was based on dipeptide matches (2-k-tup). With l-k- 
tup the search yielded the same two G-proteins as top scorers. The 
mean score then was 11.8 with a standard deviation of 4.89. 
3. RESULTS 
3.1. Hemoregulatory peptide sequence occurs in 
G-proteins 
The sequence Glu-Glu-Asp-Cys-Lys was searched 
against the MIPSX data base using the FastP program 
[9]. This sequence is that of the synthetic peptide 
HPSb. It was chosen as search sequence because the se- 
quence of the natural pentapeptide has not been deter- 
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Table I 
Homology between the Gh subunit of G-protein and hemoregulatory peptide analogs 
&-protein 
Amino acid number 
54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 
Alternative sequences: 
LYS Ile Ile His Glu Asp Gly Tyr Ser Gln Tyr . . . 
bovine Gbi Glu Glu Glu Cys Lys 
rat G~z Glu Glu Glu Cys Arg 
human G&X Glu Asp Glu Cys Lys 
Hemoregulatory peptide analogs (HP) 
HP5a pGlu Asp Asp Cys Lys 
HP5b pGlu Glu Asp Cys Lys 
HP5c Glu Glu Asp Cys Lys 
HP5d pGlu Glu Glu Cys Lys 
HP5e pGlu Asp Glu Cys Lys 
HP5f pGlu Glu Asp Cys Arg 
HP5g pGlu Glu Glu Ser Lys 
HP5h pGlu Glu Glu Cys Arg 
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mined unambiguously for positions 2 and 3 where both 
Asp and Glu are equally probable, and since HP5b is 
the most active peptide, we reasoned that it has a good 
chance to be equivalent to the natural sequence. The 
best score was found with the bovine Gi a-protein con- 
taining the sequence Glu-Glu-Glu-Cys-Lys. The second 
best score and with respect o human sequences the best 
match was also a Gi m-protein (G&3) with two conser- 
vative exchanges in positions 2 and 3 (Table I). In 
general, the sequence appears to be rare in nature, 
which strengthens the significance of the similarity to 
G-proteins. This is clearly due to the presence of the 
Cys residue. When we searched for Glu-Glu-Asp-Ser- 
Lys, the sequence of a synthetic peptide which we tested 
also in vivo and which is not active (see below), we 
found two perfect matches in the same data base. 
3.2. Biological effects 
The biological activity of several synthetic peptide 
variants was tested (Fig. 1, Table I). HP5a with the se- 
quence ~-ASP-~-ASP, that was first described by 
Paukovits et al. 1980 [lo] turned out to be inactive. The 
same was the case with only Glu as N-terminal residue, 
which also occurs when the PyroGlu-ring is split en- 
zymatically [ 111. Replacement of Cys with Ser also led 
to a complete loss of inhibition of CFU-GM cells 
(HPSg). This shows that Cys is vital for the activity of 
the peptide. All other sequences had an inhibitory ef- 
fect on myelopoietic colony formation, partly ex- 
hibiting a characteristic bell-shaped curve. This shows 
that conservative exchanges uch as Glu-Asp or Lys- 
Arg are tolerated to some extent. However it appears 
that there are quantitative differences in activity. For 
instance HP5h which was synthesised to match the se- 
quence in rat G~z appeared to be an active compound 
12 
and in general the more the sequence resembles that of 
the G proteins, the higher the activity appears to be. No 
direct toxicity was found when bone marrow cells were 
exposed to the tested peptide concentrations in suspen- 
sion culture in Eagle Dulbecco’s medium for l-24 h as 
tested by the Trypan blue exclusion assay and total cell 
counts. 
4. DISCUSSION 
It is known that the various classes of the G-proteins 
are involved in many cellular processes [12-141. They 
are also active in hemopoietic cells. For example, the Gi 
protein has recently been localized in human 
neutrophils [15]. Based on indirect studies, there is also 
evidence that hemopoietic progenitor cell proliferation 
as well as interleukin-3 and CSF-1 action are mediated 
through the same mechanism [16,17]. On this 
background it is remarkable that the synthetic analog 
oligopeptides with structural homology to G-proteins 
are able to inhibit myelopoietic colony formation. 
To assess the biological significance of this finding 
one has to consider the putative role of this sequence 
for the function of the Gb-proteins. This sequence at 
positions 63-68 is well conserved among the three Gb- 
proteins sequenced thus far but not found to that extent 
in all other G- or G-like proteins. This sequence is im- 
mediately adjacent to the well-conserved Halliday 
region A which has been implicated by three- 
dimensional analysis in p21 ras and EF-Tu as the 
phosphate binding domain. Since this sequence is not 
conserved in the well-characterized small GTP-binding 
proteins, little can be said about its context in the three- 
dimensional structure. From its position and its polar 
composition one can only guess that it might be an ex- 
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Fig. 1. Effects of the different peptides (HPSa-g) on myelopoietic 
colony formation (CFU-GM) expressed as percent of controls f SE. 
posed helical loop near the phosphate binding cleft. 
Furthermore, because of the variability of this N- 
terminal region in G-like proteins, the region between 
Halliday A and C domains is thought to be involved in 
effector interactions to account for the specific role of 
each G-protein. 
It is remarkable that the hemoregulatory factor con- 
sists of a sequence that can be found in G-proteins. 
Since the homology is confined to Gh-proteins, it 
might suggest a possible way for functioning of the 
peptide. Peptides of that size can efficiently mimic a 
binding site for another protein as it was shown for the 
synthetic pentapeptide from laminin which binds effi- 
ciently to the laminin receptor and competes with 
laminin [18]. On the other hand it has been shown that 
binding of an oligopeptide can interfere with signal 
transduction. The wasp toxin mastoparan activates a 
G-protein presumably because its sequence resembles 
that of the binding site of the receptor [19]. Since 
hemoregulatory peptide resembles the G-protein part 
that binds to an effector (or receptor), it could for in- 
stance interfere with G-protein-effector binding and 
thus override a signal coming from a receptor through 
the G-protein. Alternatively, the peptide could directly 
activate the effector by mimicking the active G-protein- 
effector complex. In this case the peptide regulator 
would bypass the normal signal mediated through 
receptor/G-protein interaction. 
It seems conflicting with the model we propose here 
that the best homology is not found with a human Gb 
protein, but with that of rat, although Gin3 can be con- 
nected to the hemopoietic system. Its amino acid se- 
quence has been deduced from the nucleotide sequence 
of a human cDNA clone isolated from a differentiated 
HL-60 cDNA library [20]. A G-protein has also been 
demonstrated in erythrocyte Gki where it is involved in 
receptor regulated K+-channels [21]. It is not unlikely 
in view of the large number of existing G-proteins that 
another G-protein in hemopoietic precursor cells is 
identical to the rat protein. On the other hand for the 
mechanism we envisage here it is not necessary that the 
oligopeptide is identical to the G-protein sequence. A 
change in one amino acid could increase the binding of 
the peptide to its target relative to that of the G-protein. 
The consequence would be that very low concentrations 
of the peptide would be able to interfere with signal 
transduction. 
It should also be noted that the analog peptides are 
not only acting on hemopoietic cells, although they res- 
pond with a high degree of selectivity in the lower dose 
range. Thus, a variety of other cell types are inhibited, 
although to a lesser degree and at higher concentrations 
[22]. This could further indicate that the peptides are 
either part of or are able to interfere with a general 
principle for proliferative regulation. 
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